摘要
目的探讨左乙拉西坦对癫患儿血清超敏C反应蛋白(hs-CRP)、S100B蛋白的影响。方法 60例癫患儿随机分为对照组30例,观察组30例。对照组采用丙戊酸钠治疗,观察组采用左乙拉西坦治疗。于治疗前和治疗6个月测定患儿血清hs-CRP和S100B蛋白的表达。结果 2组临床疗效比较,观察组控制9例,显效18例,无效3例,总有效率为90.0%;对照组控制5例,显效17例,无效8例,总有效率为73.3%,2组比较差异有统计学意义(P<0.05)。观察组治疗后患儿血清hs-CRP和S100B蛋白分别为(1.38±0.61)mg.L-1和(0.516±0.204)μg.L-1,对照组治疗后分别为(2.96±1.42)mg.L-1和(0.674±0.216)μg.L-1,2组均较治疗前下降,且观察组降低程度较对照组更明显(P<0.05)。结论左乙拉西坦可通过降低hs-CRP和S100B蛋白的表达,减轻癫患儿炎性反应,从而减轻脑损伤,效果优于丙戊酸钠。
Objective To study the effectiveness of levetiracetam on serum high -sensitivity C -reactive protein（ hs -CRP） and S100B in children with epilepsy. Methods Sixty children with epilepsy were randomly divided into control group（ n = 30） and the observation group （n = 30 ）. The children in the control group were treated with sodium valproate, while the children in the observation group were treated through levetiracetam. The serum hs - CRP and S100B were detected before and after treatment. Results The observation group the condition of 9 cases got controlled, markedly effective in 18 cases, 3 cases ineffective. In the control group the condition of 5 cases got controlled, markedly effective in 17 cases ,8 cases ineffective. The total effective rate was 90.0% in the treatment group and 73.3% in the control group. There was a significant difference between 2 groups （P 〈 0.05 ）. The hs - CRP and S100B were decreased after treatment in both groups. There was a significant difference between 2 groups （ P 〈 0.05 ）. Conclusions Levetiracetam can improve brain damage through mitigating inflammatory reactions by down regulating the expression of hs- CRP and S100B, and its effect is better than that of sodium valproate.
出处
《实用儿科临床杂志》
CAS
CSCD
北大核心
2012年第23期1845-1846,共2页
Journal of Applied Clinical Pediatrics
